ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage
 

Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a biomarker associated with heart damage, at one month after their last chemotherapy dose compared with those who did not take an ACE inhibitor, according to a study presented at the American College of Cardiology's Annual Scientific Session.

More...